Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals

UK Biotech Completes Impressive Series C

Executive Summary

Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

You may also be interested in...



Repare Gets Cash And Validation In DNA Damage Repair Alliance With Roche

Roche is paying $125m upfront to in-license potential blockbuster lead candidate camonsertib from Repare, which calls it a best-in-class ATR inhibitor and has the chance to opt back in on US commercialization.

BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal

Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.

Pfizer Ventures On Striking A Balance Between Strategic And Financial Interests

VC Playbook: Pfizer Ventures senior managing partner Barbara Dalton shares insights into how the corporate venture group balances a dual mandate, the trade-offs needed and what success looks like for a CVC.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel